Strategic Partnerships Recent leadership changes and a focus on corporate development with an Executive Chairman indicate a priority on strategic partnerships and licensing opportunities, presenting a strong opening for BD outreach to pharma manufacturers, contract development and manufacturing organizations, and academic collaborators.

Neurology and Ophthalmology Focus Product candidate migaldendranib targets diabetic macular edema and neovascular AMD, highlighting a strong addressable market in ophthalmology with potential cross-sell opportunities into neuro-ophthalmology and related inflammatory indications for precision delivery platforms.

Phase II Momentum Positive Phase II results and FDA alignment for a pivotal program create credibility for discussions around co-development, licensing or funded development deals with larger partners seeking late-stage opportunities in ophthalmic and inflammatory diseases.

Regional and Clinical Outreach Active participation in major ophthalmology and radiology/conference forums (EURETINA, MaculArt, ARVO, SNMMI) signals ongoing clinical data generation and messaging opportunities for partnerships with CROs, contract sales organizations, and ophthalmology-focused distributors.

Funding and Growth Readiness With a disclosed revenue range and $50M funding, Ashvattha appears positioned to pursue collaborations or non-dilutive funding avenues, making it attractive for strategic investors and financial partners seeking innovative, dendrimer-based therapies.